1 of 1
Story summary
- Archimed will acquire Esperion Therapeutics for about $1.1 billion, paying $3.16 per share.
- The offer is a 58% premium to the April 30, 2026 close and sent the stock up roughly 55%.
- Shareholders may receive $100 million in contingent rights if 2027 cholesterol-drug sales exceed $350 million and Enbumyst reaches $160 million by Dec. 31, 2030.
- Esperion’s board unanimously approved the deal, slated to close in Q3 2026, after which the company will go private and delist from Nasdaq.
